These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Charitable Choice regulations applicable to states receiving Substance Abuse Prevention and Treatment Block Grants, Projects for Assistance in Transition from Homelessness formula grants, and to public and private providers receiving discretionary grant funding from SAMHSA for the provision of substance abuse services providing for equal treatment of SAMHSA program participants. Final rule. Substance Abuse and Mental Health Services Administration, HHS Fed Regist; 2003 Sep; 68(189):56429-49. PubMed ID: 14518496 [TBL] [Abstract][Full Text] [Related]
23. Buprenorphine for cocaine and opiate dependence. Kosten TR; Rosen MI; Schottenfeld R; Ziedonis D Psychopharmacol Bull; 1992; 28(1):15-9. PubMed ID: 1609037 [TBL] [Abstract][Full Text] [Related]
24. Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements. Final rule. Substance Abuse and Mental Health Services Administration (SAMHSA), HHS Fed Regist; 2016 Sep; 81(187):66191-6. PubMed ID: 27726319 [TBL] [Abstract][Full Text] [Related]
25. The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention. Altice FL; Sullivan LE; Smith-Rohrberg D; Basu S; Stancliff S; Eldred L Clin Infect Dis; 2006 Dec; 43 Suppl 4():S178-83. PubMed ID: 17109304 [TBL] [Abstract][Full Text] [Related]
26. Fiscal year (FY) 1999 funding opportunities. Substance Abuse and Mental Health Services Administration, HHS. Notice of funding availability. Fed Regist; 1999 Mar; 64(46):11935-8. PubMed ID: 10557616 [TBL] [Abstract][Full Text] [Related]
27. Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. Koch AL; Arfken CL; Schuster CR Drug Alcohol Depend; 2006 Jul; 83(3):274-8. PubMed ID: 16413146 [TBL] [Abstract][Full Text] [Related]
28. Buprenorphine diffusion: the attitudes of substance abuse treatment counselors. Knudsen HK; Ducharme LJ; Roman PM; Link T J Subst Abuse Treat; 2005 Sep; 29(2):95-106. PubMed ID: 16135338 [TBL] [Abstract][Full Text] [Related]
29. Fiscal year (FY) 1999 funding opportunities. Substance Abuse and Mental Health Services Administration, HHS. Notice of funding availability. Fed Regist; 1999 Mar; 64(45):11478-83. PubMed ID: 10557617 [TBL] [Abstract][Full Text] [Related]
30. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications. Bruce RD; Dvoryak S; Sylla L; Altice FL Int J Drug Policy; 2007 Aug; 18(4):326-8. PubMed ID: 17689382 [TBL] [Abstract][Full Text] [Related]
31. Methadone versus buprenorphine for the treatment of opioid abuse in pregnancy: science and stigma. Holbrook AM Am J Drug Alcohol Abuse; 2015; 41(5):371-3. PubMed ID: 26154531 [TBL] [Abstract][Full Text] [Related]
32. Managing opioid addiction with buprenorphine. Donaher PA; Welsh C Am Fam Physician; 2006 May; 73(9):1573-8. PubMed ID: 16719249 [TBL] [Abstract][Full Text] [Related]
33. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians. Arfken CL; Johanson CE; di Menza S; Schuster CR J Subst Abuse Treat; 2010 Sep; 39(2):96-104. PubMed ID: 20598829 [TBL] [Abstract][Full Text] [Related]
34. Medication Assisted Treatment for Opioid Use Disorders. Final rule. Substance Abuse and Mental Health Services Administration, HHS Fed Regist; 2016 Jul; 81(131):44711-39. PubMed ID: 27400463 [TBL] [Abstract][Full Text] [Related]
35. Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. Schackman BR; Merrill JO; McCarty D; Levi J; Lubinski C Clin Infect Dis; 2006 Dec; 43 Suppl 4():S247-53. PubMed ID: 17109311 [TBL] [Abstract][Full Text] [Related]
36. Cooperative agreement with Policy Research, Inc., to continue the National GAINS Center for People with Co-Occurring Disorders in the Justice System. Center for Substance Abuse Treatment (CSAT) and Center for Mental Health Services (CMHS), Substance Abuse and Mental Health Services Administration (SAMHSA), HHS. Fed Regist; 1999 Apr; 64(77):19799. PubMed ID: 10558478 [TBL] [Abstract][Full Text] [Related]
37. Substance Abuse and Mental Health Services Administration; requirements applicable to protection and advocacy of individuals with mental illness; final rule--Center for Mental Health Services, SAMHSA. Final rule. Fed Regist; 1997 Oct; 62(199):53548-71. PubMed ID: 10177296 [TBL] [Abstract][Full Text] [Related]
38. Methadone in maintenance treatment of narcotic addicts; joint revision of conditions for use; interim maintenance treatment; human immunodeficiency virus disease counseling--FDA and SAMHSA. Final rule. Fed Regist; 1993 Jan; 58(3):495-9. PubMed ID: 10171334 [TBL] [Abstract][Full Text] [Related]
39. Factors associated with Medicaid patients' access to buprenorphine treatment. Baxter JD; Clark RE; Samnaliev M; Leung GY; Hashemi L J Subst Abuse Treat; 2011 Jul; 41(1):88-96. PubMed ID: 21459544 [TBL] [Abstract][Full Text] [Related]
40. Buprenorphine: effective treatment of opioid addiction starts in the office. Fiellin DA Am Fam Physician; 2006 May; 73(9):1513-4. PubMed ID: 16719242 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]